Apimeds Pharmaceuticals US (APUS) Notes Payables (2023 - 2026)

Apimeds Pharmaceuticals US (APUS) has reported Notes Payables for 4 consecutive years, with $8.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Notes Payables changed N/A year-over-year to $8.9 million; the trailing twelve-month figure through Jun 2026 stood at $8.9 million (changed N/A YoY), and the FY2025 full-year result was $7.1 million, up 2736.51% from the prior year.
• Notes Payables climbed to $8.9 million in Q2 2026 per APUS's latest filing, from $7.1 million in the prior quarter.
• Across five years, Notes Payables topped out at $8.9 million in Q2 2026 and bottomed at $250000.0 in Q4 2024.
• Historically, Notes Payables has averaged $3.4 million across 4 years, with a median of $373620.0 in 2025.
• The sharpest annual moves came in 2024 and 2025: Notes Payables slipped 6.33% in 2024, then jumped 2736.51% in 2025.
• Over 4 years, Notes Payables stood at $266891.0 in 2023, then decreased by 6.33% to $250000.0 in 2024, then surged by 2736.51% to $7.1 million in 2025, then rose by 25.61% to $8.9 million in 2026.
• According to Business Quant data, Notes Payables over the past three periods registered $8.9 million, $7.1 million, and $373620.0 for Q2 2026, Q4 2025, and Q1 2025 respectively.